Related Experiment Video

Updated: Jun 20, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

[Apoptosis resistance in malignant tumors: novel apoptosis-based therapeutic approaches]

W Roth1

  • 1Pathologisches Institut, Universität Heidelberg und Deutsches Krebsforschungszentrum Heidelberg, Im Neuenheimer Feld 220/221, 69120 Heidelberg. wilfried.roth@med.uni-heidelberg.de

Der Pathologe
|September 17, 2009
PubMed

Insights

Defects in apoptotic cell death pathways drive cancer development and therapy resistance. Understanding these mechanisms is crucial for developing new cancer treatments and improving patient prognosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Context:

  • Apoptosis (programmed cell death) defects are implicated in cancer initiation and progression.
  • Therapy resistance, including to chemotherapy and radiotherapy, is a major challenge in cancer treatment.
  • Understanding the molecular underpinnings of apoptosis resistance is critical for clinical success.

Purpose:

  • To investigate the molecular mechanisms of apoptosis resistance in cancer cells.
  • To identify key anti-apoptotic proteins contributing to therapeutic resistance.
  • To explore strategies for overcoming apoptosis resistance and sensitizing cancer cells to treatment.

Summary:

  • Defective apoptotic signaling pathways are a significant cause of cancer and contribute to resistance against chemo- and radiotherapy.
  • Identifying and understanding the regulation of anti-apoptotic proteins is essential for developing novel therapeutic strategies.
  • Expression profiles of apoptosis-regulating proteins may serve as prognostic biomarkers in cancer patients.

Impact:

  • Provides insights into the molecular basis of cancer therapy resistance.
  • Facilitates the development of novel strategies to enhance cancer treatment efficacy.
  • Highlights the potential of apoptosis-regulating proteins as prognostic indicators for patient outcomes.

More Related Videos

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.